Cost Effectiveness of Pramipexole in Parkinson’s Disease in the US

被引：0
|
作者：
Thomas J. Hoerger
Mohan V. Bala
Clayton Rowland
Marianne Greer
Elizabeth A. Chrischilles
Robert G. Holloway
机构：
[1] Research Triangle Institute,Center for Economics Research
[2] Centocor Inc.,Outcomes Research
[3] Pharmacia & Upjohn Inc.,Global Health Economics
[4] Boehringer Ingelheim Pharmaceuticals,Corporate Health Economics
[5] Inc.,Department of Preventive Medicine and Environmental Health
[6] University of Iowa,Department of Neurology
[7] University of Rochester,undefined
来源：
PharmacoEconomics | 1998年 / 14卷
关键词：
Levodopa; Adis International Limited; Bromocriptine; Pramipexole; Unify Parkinson Disease Rate Scale;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: Pramipexole was recently approved in the US for treatment of the symptoms of idiopathic Parkinson’s disease (PD). Although pramipexole has been found to be safe and efficacious when compared with placebo, little data are yet available on its cost effectiveness when compared with baseline treatment. The aim of this study was to estimate the costs and cost effectiveness (cost utility) of pramipexole compared with baseline treatment in patients with early and advanced PD.
引用
收藏
页码：541 / 557
页数：16
相关论文
共 50 条
  • [1] Cost effectiveness of pramipexole in Parkinson's disease in the US
    Hoerger, TJ
    Bala, MV
    Rowland, C
    Greer, M
    Chrischilles, EA
    Holloway, RG
    [J]. PHARMACOECONOMICS, 1998, 14 (05) : 541 - 557
  • [2] Cost-effectiveness analysis of pramipexole in early Parkinson's disease
    Noyes, K
    Dick, AW
    Holloway, RG
    [J]. VALUE IN HEALTH, 2003, 6 (03) : 274 - 274
  • [3] Cost-effectiveness of pramipexole in Parkinson's disease in the United States
    Hoerger, TJ
    Bala, MV
    Rowland, C
    Greer, M
    Holloway, R
    [J]. NEUROLOGY, 1998, 50 (04) : A298 - A299
  • [4] Pramipexole and levodopa in early Parkinson's disease - Dynamic changes in cost effectiveness
    Noyes, K
    Dick, AW
    Holloway, RG
    [J]. PHARMACOECONOMICS, 2005, 23 (12) : 1257 - 1270
  • [5] Cost-effectiveness of pramipexole compared with piribedil in early Parkinson's disease patients
    Chikina, ES
    Gusev, EL
    Belousov, YB
    Guecht, AB
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 321 - 321
  • [6] COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON'S DISEASE
    Belousov, D.
    Afanasieva, E.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A757 - A757
  • [7] Pramipexole and levodopa in early parkinson’s diseaseDynamic changes in cost effectiveness
    Katia Noyes
    Andrew W. Dick
    Robert G. Holloway
    [J]. PharmacoEconomics, 2005, 23 : 1257 - 1270
  • [8] Clinical effectiveness of pramipexole on depressive symptoms in Parkinson's disease
    Parise, V. Fricchione
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S397 - S398
  • [9] The effectiveness of pramipexole and levodopa as an initial treatment for Parkinson's disease
    Oztekin, N. S.
    Oztekin, M. F.
    Polat, R. S.
    Renkliyildiz, B.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S237 - S237
  • [10] The effectiveness of pramipexole and cabergoline as an adjunct to levodopa in Parkinson's disease
    Oztekin, N.
    Oztekin, M. F.
    Sarl-Polat, R.
    Orhan, G.
    Ak, F.
    [J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 : S106 - S107
12345